ABT Abbott Laboratories Loading...

From PODD earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Aug 05 ◎
Ashley McEvoy CEO, Insulet Corporation PODD Q2 FY26 call
Management admits its guidance was set on flawed assumptions for Type 2 retention and is now assuming no improvement in attrition trends in the second half, suggesting the problem is partially structural. — This signals a material demand signal for CGM/diabetes ecosystem, potentially impacting companies like Abbott that view the Type 2 market as a key growth vector.
ABT
MED
12:00
May 06 ◎
Ashley McEvoy CEO, Insulet Corporation PODD Q1 FY26 call
Abbott's Libre 3 Plus integration expands Insulet's addressable market to 450,000 additional users, highlighting the strategic partnership's importance.
ABT
HIGH
13:00
Feb 18 ◎
Ashley McEvoy President and Chief Executive Officer, Insulet Corporation PODD Q4 FY25 call
Integration with Abbott's Libre 3+ expands Omnipod 5's CGM compatibility, reinforcing partnership and potentially boosting Abbott's sensor volume.
ABT
HIGH

About ABT Analyst Coverage

Buzzberg tracks ABT (Abbott Laboratories) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: Ashley McEvoy.